Innovative Technology Platform miDiagnostics leverages advanced silicon chip technology and nanofluidic processors to develop rapid, easy-to-use laboratory-quality diagnostic tests. This innovative platform enables versatile biomarker detection from simple samples, presenting opportunities to expand into new testing markets such as infectious diseases, oncology, and chronic conditions.

Strong Recent Funding With a recent €30 million Series D funding round led by Thermo Fisher Scientific and additional investments totaling over $32 million, miDiagnostics demonstrates robust financial backing. This financial strength provides the capacity to accelerate product development, expand sales efforts, and pursue strategic partnerships across diverse healthcare settings.

Growing Market Presence The successful pilot studies at Brussels Airport and the launch of CE-IVD certified COVID-19 tests indicate a promising entry into point-of-care diagnostics, especially in high-traffic environments requiring rapid testing solutions. These initiatives position miDiagnostics to target both institutional and consumer markets seeking fast, reliable diagnostic testing.

Collaborative Development Strategic collaborations with industry leaders like Galapagos for CAR-T sterility testing showcase miDiagnostics' focus on integrating its technology into advanced medical applications. This opens opportunities to partner with pharmaceutical and biotech companies for personalized medicine, cellular therapies, and hospital-based diagnostics.

Market Differentiation miDiagnostics’ focus on miniaturized, connected testing solutions set it apart from traditional lab diagnostics and larger equipment manufacturers. Its emphasis on point-of-care applications in infectious disease screening, monitoring, and emerging health conditions suggests significant sales opportunities in global health markets, telemedicine, and remote patient monitoring sectors.